Reuters logo
BRIEF-Promius Pharma says ZEMBRACE® SymTouch® achieves primary endpoint
November 15, 2017 / 2:14 PM / in a month

BRIEF-Promius Pharma says ZEMBRACE® SymTouch® achieves primary endpoint

Nov 15 (Reuters) - Promius Pharma LLC

* announces ZEMBRACE® SymTouch® (sumatriptan injection) 3 mg achieves primary endpoint in post-approval clinical trial Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below